NewslettersMuscle Cell NewsDyne Therapeutics Announces First Patient Dosed in Phase I/II DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular DystrophyBy Bob - September 19, 20220196Dyne Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial, DELIVER, evaluating DYNE-251 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 51 skipping.[Dyne Therapeutics, Inc.]Press Release